Startup data
| Business model | |
|---|---|
| Country | |
| Investment Received | |
| Scope | |
| Revenues | |
| Startup stage | |
| Tecnhologies | |
| Verticals |
BEAT Therapeutics
€0,00
Description: BEAT Therapeutics is a biopharmaceutical startup founded in 2023 and driven by an unwavering commitment to transforming cancer care. Our mission is to provide a more effective therapeutic option for patients facing hard-to-treat cancers, for whom there are no alternatives other than unsuccessful conventional therapies, resulting in staggeringly low survival rates. Our first drug candidate, BBIT20, is a FIRST-IN-CLASS therapy that targets the BRCA1/BARD1 interaction, a highly validated therapeutic target in cancer. With a precise mechanism of action that is more effective, less toxic, and successful against chemotherapy-resistant cells, our therapy will set a new standard of care and redefine the possibilities in oncology. We are committed to standing as a new hope to improve the quality of life of oncology patients. BEAT Therapeutics: BEATing hard on cancer!
Web: https://www.linkedin.com/company/beat-therapeutics/
Videopitch: https://youtu.be/TlKShx4A7DA
